Patent Strategy for MedTech Companies: Balancing Patent Protection with Regulatory Approval

Introduction : A significant proportion of technological advancements in the healthcare sector have been driven by medical devices. Over recent decades, these tools have radically changed how doctors and clinical teams identify health issues, prevent illness, track patient progress, and deliver therapy.

Under the framework set out by the World Health Organisation (WHO), medical devices encompass a wide array of physical instruments, diagnostic apparatuses, software systems, and healthcare implements. They are designed for specific medical uses, such as identifying diseases, supporting physiological processes, or modifying physical structures in the body, accomplishing their primary clinical task through physical, mechanical, structural, or electronic means, unlike pharmaceuticals interacting with the body’s metabolic or immune system.

Medical devices range from simpler basic disposable supplies like examination gloves, hypodermic syringes and tongue depressors to complex hardware like automated insulin pumps, surgical cameras, implantable pacemakers, life-support units, and computer - guided surgical platforms.

Developing a medical device requires significant R&D investment, making strong patent coverage essential for efficient commercial returns and to recoup investment. However, medtech commercialisation has an essential prerequisite, which is mandatory regulatory approval. Innovators cannot lawfully sell a medical product without first securing formal regulatory approvals. This article, therefore, seeks to outline a strategic pathway for securing and protecting medical device innovations by aligning patent filing strategies with key regulatory approval milestones.

Regulatory Due Diligence: Determining the Applicable Regulatory Pathway

Before commencing manufacturing or filing patent applications, medtech companies should first determine whether their product qualifies as a medical device under the applicable regional legal framework where commercialisation is intended. This is a crucial preliminary step, as the regulatory obligations governing medical devices arise only when a product falls within the statutory definition of “medical device” as prescribed in the relevant jurisdiction. Since these definitions vary across countries, the legal status of a product must be assessed separately in each market. For instance, in India, a product is classified as a medical device if it satisfies the definition under Rule 3(zb) of the Medical Devices Rules, 2017, whereas in the United States, the applicable definition is contained in Section 201(h) of the Federal Food, Drug, and Cosmetic Act.

Once the product comes under the ambit of the definition of medical device, the manufacturer must determine the product's precise risk class. Regulatory pathways, such as clinical trials, pre-market notices, and labelling obligations, and quality management systems depend directly on this classification. India’s Medical Devices Rules (2017) divide products into four tiers (Class A low risk up to Class D high risk); similarly, the US FDA adopts a three-tier structure ranging from Class I through Class III (Class I low risk to Class III high risk), with increasing regulatory requirements and stringent oversight as the class increases.

It is recommended to list the device’s intended use and clinical indications to determine the class where the device falls. Examining existing predicate devices already on the market offers a practical baseline for mapping out the appropriate compliance track.

Strategic Trajectory for Securing Intellectual Property Rights in Medical Devices

In the aspect of patentability of a medical device, innovators should consider filing a provisional patent application before initiating the regulatory approval process, as regulatory authorities generally require extensive technical documentation, clinical data and performance-related information to establish the safety and efficacy of a medical device, which if disclosed to public authorities before filing of patent application amounts to public disclosure; constituting prior art, thereby jeopardising the novelty of the invention and rendering it unpatentable. Filing a provisional application at an early stage secures a priority date while preserving the inventor's right to develop the invention further. A complete specification may be filed anytime within the prescribed 12-month period.

This approach offers two distinct practical advantages

It allows applicants to incorporate technical modifications made during clinical testing without losing their original priority date, provided these additions remain within the scope of the provisional application.

The extra twelve-month window between the filing of the provisional and complete specification may be used to obtain the necessary regulatory clearances, minimising the erosion of the effective patent term.

In jurisdictions like the US, continuation applications provide additional flexibility. Continuation applications allow applicants to modify or add claims based on the original pending application any time before the grant of a patent, thereby allowing the patent scope to align with evolving product developments and regulatory requirements.

In India, medical devices to be patentable; apart from establishing novelty, inventive step (non-obviousness), and industrial utility, applicants should ensure that the invention does not fall within the exclusions from patentability under Section 3 of the Act; particular attention in the context of medical devices may be paid to section3(k),3(i) and 3(f)

While Section 3(k) bars computer programs per se, courts have clarified this boundary. In Ferid Allani v. Union of IndiaThe Delhi High Court ruled that software-based inventions can be patented if they demonstrate a clear technical effect or contribution. Further, it has been clarified in BlackBerry Limited v. Assistant Controller of Patents that improvements in processing speed, system efficiency, or operational performance constitute a technical effect.

Section 3(i) prohibits patenting methods of medicinal, surgical, therapeutic, or diagnostic treatment performed on humans or animals. While the medical device itself may be patentable, the applicant must ensure that claims drafted do not include clinical procedures or treatment steps.

As a precautionary measure in case of an objection raised, it is advisable for the applicant to be able to adequately demonstrate that the claimed invention is not merely an aggregation or duplication of known components, each performing its function independently without any synergistic effect, as such subject matter is excluded from patentability under Section 3(f).

Patent filing tactics should be in line with expected worldwide markets and regulatory processes, since medical technology businesses often pursue commercialisation across many jurisdictions. In this context, medical device manufacturers should consider filing an international application under the Patent Cooperation Treaty (PCT) simultaneously after filing a complete specification within twelve months to preserve the priority date of the filed provisional application. While a PCT application does not itself culminate in the grant of patents in the designated jurisdictions, it preserves the opportunity to seek protection across conventional countries. Thereafter, manufacturers may utilise the 30 to 31 months available before entering the national or regional phase to evaluate the commercial potential of the invention, assess the likelihood of obtaining the requisite regulatory approvals, analyse market conditions in the intended jurisdictions, and weigh other commercial and economic considerations. Such an assessment enables applicants to effectively decide the jurisdictions to file regional applications.

Indian applicants must also note the requirement of Section 39 of the Patents Act

If the application is first filed in India, the applicant must wait six weeks before making foreign or PCT filings, provided no Secrecy Directions are issued by the Patent Office.

If commercial strategy requires filing abroad first, the applicant must apply for a Foreign Filing License (FFL) using Form 25 before making the foreign submission.

Applicants must also keep the Indian Patent Office informed about counterpart foreign applications under Section 8, handled via Form 3. Under the Patents (Amendment) Rules, 2024, applicants must submit updated Form 3 details within three months of the First Examination Report (FER) being issued. Additionally, if the Controller requests prosecution updates under Section 8(2), Rule 12(4) requires a response within two months.

Beyond patents, it is beneficial to build a multi-layered intellectual property strategy, like registering Trademarks to Safeguard brand names, product identities, and commercial reputation and registering designs to protect novel shapes, visual contours, and ergonomic designs.

Maximising Patent Life and Commercial Exclusivity

Patents grant owners the legal right to exclude others from making, using, offering for sale, or selling a protected technology for a set period. This legal exclusivity helps businesses recover substantial R&D costs.

However, because clinical trials and regulatory reviews often consume several years of the 20-year patent term, medical device companies must actively manage their portfolios to preserve commercial value.

In India, innovators can use the Patent of Addition pathway under Section 54 of the Patents Act. This mechanism secures protection for modifications, updates, or technical improvements linked to a main patent, helping manufacturers defend product updates throughout the device's lifecycle.

In jurisdictions like the United States, companies can apply for Patent Term Extension (PTE) to restore terms lost to regulatory review. PTE can restore up to five years of patent term, provided total effective exclusivity after approval does not exceed 14 years. It is important to note that extension rules permit only one patent per approved product to receive PTE; hence, companies should strategically select the patent covering their core technology, key claims, or long-term design features.

Conclusion

In conclusion, securing intellectual property protection for medical devices requires a holistic and strategically planned approach. Innovators must align their patent strategies with regulatory approval timelines, jurisdiction-specific regulatory requirements and the applicable patent law standards governing patentability and procedural compliance. Effective protection further requires consideration of complementary forms of intellectual property protection to safeguard the commercial value of the innovation. Given the evolving nature of medical technologies, adopting a product lifecycle approach by protecting subsequent improvements and modifications enables manufacturers to maintain exclusivity and maximise the long-term value of their innovations.

Author :- Harini Srinivasan, in case of any query, contact us at Global Patent Filing or write back us via email at support@globalpatentfiling.com.

Endnotes

1. World Health Organization, WHO Global Model Regulatory Framework for Medical Devices including In Vitro Diagnostic Medical Devices (WHO 2017) https://www.who.int/publications/i/item/9789241512350 accessed 7 August 2026.
2. Medical Devices Rules, 2017, rr 3(zb), 4–7; Federal Food, Drug, and Cosmetic Act, 21 USC § 321(h) (defining "device"); US Food and Drug Administration, Device Classification https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device accessed 7 August 2026.
3. Patents Act 1970, ss 3(f), 3(i), 3(k), 39, 54 and 8; Patents Rules 2003, rr 12 and 71 (as amended by the Patents (Amendment) Rules 2024); Ferid Allani v Union of India 2019 SCC OnLine Del 11867; BlackBerry Ltd v Assistant Controller of Patents and Designs 2024 SCC OnLine Del 1973.
4. Patent Cooperation Treaty (adopted 19 June 1970, entered into force 24 January 1978) 1160 UNTS 231, arts 3, 22 and 39; World Intellectual Property Organization, Protecting Your Inventions Abroad: Frequently Asked Questions About the PCT https://www.wipo.int/pct/en/faqs/ accessed 7 August 2026.
5. 35 USC § 156 (Patent Term Extension); United States Patent and Trademark Office, Patent Term Extension under 35 U.S.C. §156 https://www.uspto.gov/patents/laws/patent-term-extension accessed 7 August 2026.
6. World Intellectual Property Organization, World Intellectual Property Indicators 2024 (WIPO 2024) https://www.wipo.int/publications/en/details.jsp?id=4701 accessed 7 August 2026; World Intellectual Property Organization, Making Intellectual Property Work for Medical Technology https://www.wipo.int/ip-outreach/en/ipday/2021/medical-technology.html accessed 7 August 2026